Publication:
Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors.

dc.contributor.authorRoyo-Cebrecos, Cristina
dc.contributor.authorLaporte-Amargós, Julia
dc.contributor.authorPeña, Marta
dc.contributor.authorRuiz-Camps, Isabel
dc.contributor.authorPuerta-Alcalde, Pedro
dc.contributor.authorAbdala, Edson
dc.contributor.authorOltolini, Chiara
dc.contributor.authorAkova, Murat
dc.contributor.authorMontejo, Miguel
dc.contributor.authorMikulska, Malgorzata
dc.contributor.authorMartín-Dávila, Pilar
dc.contributor.authorHerrera, Fabian
dc.contributor.authorGasch, Oriol
dc.contributor.authorDrgona, Lubos
dc.contributor.authorMorales, Hugo Manuel Paz
dc.contributor.authorBrunel, Anne-Sophie
dc.contributor.authorGarcía, Estefanía
dc.contributor.authorIsler, Burcu
dc.contributor.authorKern, Winfried V
dc.contributor.authorPalacios-Baena, Zaira R
dc.contributor.authorde la Calle, Guillermo Maestro
dc.contributor.authorMontero, Maria Milagro
dc.contributor.authorKanj, Souha S
dc.contributor.authorSipahi, Oguz R
dc.contributor.authorCalik, Sebnem
dc.contributor.authorMárquez-Gómez, Ignacio
dc.contributor.authorMarin, Jorge I
dc.contributor.authorGomes, Marisa Z R
dc.contributor.authorHemmatti, Philipp
dc.contributor.authorAraos, Rafael
dc.contributor.authorPeghin, Maddalena
dc.contributor.authorDel Pozo, José Luis
dc.contributor.authorYáñez, Lucrecia
dc.contributor.authorTilley, Robert
dc.contributor.authorManzur, Adriana
dc.contributor.authorNovo, Andrés
dc.contributor.authorCarratalà, Jordi
dc.contributor.authorGudiol, Carlota
dc.contributor.authorIRONIC study group
dc.date.accessioned2023-05-03T14:20:02Z
dc.date.available2023-05-03T14:20:02Z
dc.date.issued2022-09-30
dc.description.abstractObjectives: To assess the clinical features and outcomes of Pseudomonas aeruginosa bloodstream infection (PA BSI) in neutropenic patients with hematological malignancies (HM) and with solid tumors (ST), and identify the risk factors for 30-day mortality. Methods: We performed a large multicenter, retrospective cohort study including onco-hematological neutropenic patients with PA BSI conducted across 34 centers in 12 countries (January 2006−May 2018). Episodes occurring in hematologic patients were compared to those developing in patients with ST. Risk factors associated with 30-day mortality were investigated in both groups. Results: Of 1217 episodes of PA BSI, 917 occurred in patients with HM and 300 in patients with ST. Hematological patients had more commonly profound neutropenia (0.1 × 109 cells/mm) (67% vs. 44.6%; p
dc.identifier.doi10.3390/pathogens11101132
dc.identifier.issn2076-0817
dc.identifier.pmcPMC9610728
dc.identifier.pmid36297188
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610728/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2076-0817/11/10/1132/pdf?version=1664533122
dc.identifier.urihttp://hdl.handle.net/10668/21531
dc.issue.number10
dc.journal.titlePathogens (Basel, Switzerland)
dc.journal.titleabbreviationPathogens
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.organizationHospital Universitario Virgen Macarena
dc.organizationHospital Universitario Virgen Macarena
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectPseudomonas aeruginosa
dc.subjectbacteremia
dc.subjectbloodstream infection
dc.subjectcancer
dc.subjecthematologic malignancy
dc.subjectsolid tumor
dc.titlePseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9610728.pdf
Size:
295.69 KB
Format:
Adobe Portable Document Format